Serina Therapeutics, Inc. (SER)
1.65
-0.04
(-2.37%)
USD |
NYAM |
Nov 05, 16:00
Serina Therapeutics Max Drawdown (5Y) : 98.23% for Oct. 31, 2026
Max Drawdown (5Y) Chart
Historical Max Drawdown (5Y) Data
| Date | Value |
|---|---|
| October 31, 2026 | 98.23% |
| September 30, 2026 | 98.23% |
| August 31, 2026 | 98.23% |
| July 31, 2026 | 98.23% |
| June 30, 2026 | 98.23% |
| May 31, 2026 | 98.23% |
| April 30, 2026 | 98.23% |
| March 31, 2026 | 98.23% |
| February 28, 2026 | 98.23% |
| January 31, 2026 | 97.99% |
| December 31, 2025 | 97.99% |
| November 30, 2025 | 96.05% |
| October 31, 2025 | 95.67% |
| September 30, 2025 | 95.67% |
| August 31, 2025 | 95.67% |
| July 31, 2025 | 95.67% |
| June 30, 2025 | 95.67% |
| May 31, 2025 | 95.67% |
| April 30, 2025 | 95.67% |
| March 31, 2025 | 95.67% |
| February 28, 2025 | 95.63% |
| January 31, 2025 | 95.63% |
| December 31, 2024 | 95.63% |
| November 30, 2024 | 95.41% |
| October 31, 2024 | 95.20% |
| Date | Value |
|---|---|
| September 30, 2024 | 95.20% |
| August 31, 2024 | 95.20% |
| July 31, 2024 | 95.20% |
| June 30, 2024 | 95.20% |
| May 31, 2024 | 95.20% |
| April 30, 2024 | 94.86% |
| March 31, 2024 | 93.59% |
| February 29, 2024 | 93.55% |
| January 31, 2024 | 93.55% |
| December 31, 2023 | 93.55% |
| November 30, 2023 | 93.55% |
| October 31, 2023 | 91.85% |
| September 30, 2023 | 91.85% |
| August 31, 2023 | 91.85% |
| July 31, 2023 | 91.85% |
| June 30, 2023 | 91.85% |
| May 31, 2023 | 91.85% |
| April 30, 2023 | 90.30% |
| March 31, 2023 | 90.30% |
| February 28, 2023 | 90.30% |
| January 31, 2023 | 90.30% |
| December 31, 2022 | 90.30% |
| November 30, 2022 | 90.30% |
| October 31, 2022 | 90.30% |
| September 30, 2022 | 90.30% |
Max Drawdown Definition
Max drawdown is an indicator of the risk of a portfolio chosen based on a certain strategy. It measures the largest single drop from peak to bottom in the value of a portfolio before a new peak is achieved.
Max Drawdown (5Y) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Max Drawdown (5Y) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 88.96% |
| Oncolytics Biotech, Inc. | 92.83% |
| Sangamo Therapeutics, Inc. | 99.68% |
| Sarepta Therapeutics, Inc. | 93.33% |
| Anixa Biosciences, Inc. | 70.17% |
Max Drawdown (5Y) Related Metrics
| Alpha (5Y) | -55.99 |
| Beta (5Y) | 1.286 |
| Annualized Standard Deviation of Monthly Returns (5Y Lookback) | 68.78% |
| Historical Sharpe Ratio (5Y) | -0.6604 |
| Historical Sortino (5Y) | -1.224 |
| Monthly Value at Risk (VaR) 5% (5Y Lookback) | 33.59% |